Ascentage Pharma, a global biopharmaceutical company dedicated to developing novel cancer treatments, chronic hepatitis B (CHB) therapies, and age-related disease solutions, announced that it will present findings from four clinical studies involving its three key drug candidates at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO Annual Meeting is a highly anticipated event in the world of clinical oncology, showcasing cutting-edge research and advancements in cancer care.
Ascentage Pharma’s presentations will include an Oral Report featuring updated data on olverembatinib, the company’s first approved product, in patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST), a condition with limited treatment options. The company will also share detailed data on lisaftoclax in patients with acute myeloid leukemia (AML) and Waldenstrom macroglobulinemia (WM), as well as APG-2449 in patients with non-small cell lung cancer (NSCLC).
Olverembatinib, the company’s lead drug candidate, has been granted Priority Review and Breakthrough Therapy Designations by China’s Center for Drug Evaluation (CDE) and is currently included in the 2022 National Reimbursement Drug List (NRDL). It has also received Orphan Drug and Fast Track Designations from the US FDA and Orphan Designation by the EMA in the EU.
Ascentage Pharma’s commitment to research and development is evident in its robust clinical pipeline, which includes over 40 Phase I/II clinical trials, including five global registrational Phase III studies, being conducted across the US, China, Europe, and Australia. The company has been recognized for its contributions with multiple Major National R&D Projects, including Major New Drug Projects, New Drug Incubator status, Innovative Drug Programs, and a Major Project for Infectious Disease Prevention and Treatment.
With a talented team of global experts and strategic partnerships with renowned biotechnology and pharmaceutical companies, Ascentage Pharma continues to strengthen its R&D capabilities and accelerate its clinical development programs. The company’s mission is to address unmet clinical needs worldwide and bring innovative treatments to patients in need.
